XZXixi Zhao

Xixi Zhao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xixi Zhao has a total of 56 co-authors. Here are the top co-authors by number of shared publications:

  • Hongbing Ma

    Department of Hematology, West China Hospital, Sichuan University, China

    6 shared publications
  • Shangyi Geng

    Department of Radiation Oncology, The Second Affiliated Hospital of Xi’an, Jiaotong University, Xi’an, China

    6 shared publications
  • Xiaoxiao Liu

    Department of Radiation Oncology, The Second Affiliated Hospital of Xi’an, Jiaotong University, Xi’an, China

    6 shared publications
  • Yongze Dang

    Department of Radiation Oncology, The Second Affiliated Hospital of Xi’an, Jiaotong University, Xi’an, China

    6 shared publications
  • Yuchen Wang

    Department of Radiation Oncology, The Second Affiliated Hospital of Xi’an, Jiaotong University, Xi’an, China

    6 shared publications
  • Shupei Pan

    Department of Radiation Oncology, The Second Affiliated Hospital of Xi’an, Jiaotong University, Xi’an, China

    4 shared publications

Latest Publications

  • Open Access

    Association between four indirect indicators of insulin resistance and lung cancer: evidence from UK biobank and Mendelian randomization analysis

    by Yongze Dang, Xia Li, Yutong Cheng, Shupei Pan, Guoliang Li, Xiaoxiao Liu, Yuchen Wang, Xinyu He, Shangyi Geng, Hongbing Ma, et al.

    Insulin resistance (IR) has been increasingly linked to cancer development and progression, but its association with lung cancer (LC) remains unclear. This

  • Open Access

    Mapping the research landscape of the correlation between radiotherapy and tumor immune microenvironment: A bibliometric analysis

    by Shangyi Geng, Xia Li, Yongze Dang, Xinran Huang, Lintao Zhang, Xinyu He, Shupei Pan, Hongbing Ma, Xixi Zhao

    Background: Radiation therapy (RT) is a cornerstone of cancer treatment that not only directly kills tumor cells but also produces synergistic effects with immunotherapy by remodeling the tumor immune microenvironment (TIME). However, systematic bibliometric analyses of RT‐TIME interactions remain unexplored. Methods: This study analyzed all the literature related to RT and TIME from the Web of Science (WOS) Core Collection through 2024. It utilized R, VOSviewer, and CiteSpace to visually analyze authors, countries, institutions, keywords, co‐cited references, research hotspots, and frontiers. Results: China, the United States, and Germany emerged as the leading contributors, with 1,253, 581, and 162 publications, respectively. Frontiers in Immunology was the most active journal ( n = 186). Co‐occurrence analysis identified “radiotherapy” ( n = 898) and “immunotherapy” ( n = 895) as core themes, with sustained focus on “CD8(+) T cells” (citation burst = 8.81) and emerging interest in “(nature killer) NK cells.” Temporal evolution revealed three research phases: initial exploration (2007–2015) of RT's immunomodulatory mechanisms of RT, clinical validation of RT combined with Programmed Cell Death Protein 1 (PD‐1)/ Cytotoxic T‐Lymphocyte‐Associated Protein 4 (CTLA‐4) inhibitors (2015–2020), and recent diversification (2020–2024) toward technical optimization (e.g., stereotactic RT), tumor type expansion, and safety management. Conclusions: This comprehensive bibliometric analysis highlights future priorities, including exploring optimal synergistic strategies for combination therapies, investigating spatiotemporally resolved immune mechanisms, and developing predictive biomarkers. These areas are currently experiencing rapid growth and require further research.

  • Causal roles of immune cells and plasma metabolites in esophageal cancer: A Mendelian randomization study with nutritional insights.

    by Xiaoxiao Liu, Yuchen Wang, Yongze Dang, Xia Li, Shangyi Geng, Xinyu He, Hongbing Ma, Xixi Zhao

    Metabolites, as key mediators of nutrition-immune interactions, have attracted increasing interest in cancer research. However, the causal relationships between immune cells, plasma metabolites, and esophageal cancer, and their potential for guiding nutritional interventions remain unclear. We conducted a two-sample Mendelian randomization analysis using the inverse-variance weighted method to evaluate the causal effects of immune cells and plasma metabolites on esophageal cancer. We explored potential intermediary pathways by investigating associations between im-mune cell traits and plasma metabolites relevant to esophageal cancer risk. To test the robustness of our find-ings, we also carried out sensitivity analyses. We identified 19 immune cell phenotypes associated with esophageal cancer risk (8 protective, 11 risk factors). In addition, 22 plasma metabolites (including 5 ratios) were protective, while 26 metabolites (including 8 ratios) increased risk, highlighting potential targets for nutritional interventions. Our analysis identified four plasma metabolites that were associated with specific immune cell traits relevant to esophageal cancer risk. Sensitivity analyses confirmed the robustness of the findings, with no significant heterogeneity or pleiotropy observed. This study provides genetic evidence for potential causal associations among immune cells, plasma metabolites, and esophageal cancer, and identifies observed associations between immune cell traits and plasma metabolites. These findings provide a foundation for precision nutrition and support dietary modification as a promising strategy for prevention and adjunctive therapy.

  • Open Access

    Association of eczema with risk of pan-cancers: a two-sample Mendelian randomization study

    by Xixi Zhao, Xinyu He, Xiaoxiao Liu, Shangyi Geng, Yuchen Wang, Yongze Dang, Ruijuan Zhang, Xinran Huang, Wei Guo, Hongbing Ma

    Background: Both eczema and tumor are associated with immune disorders. Although several investigations have observed the relationship between eczema and certain cancers, evidence for causality is lacking. Methods: We conducted a two-sample Mendelian randomization (MR) study to examine and explore the genetic association between eczema and pan-cancers. Upon satisfying the three core assumptions of MR, we analyzed the causality between eczema and 15 site-specific cancers utilizing an inverse variance weighted method. We verified the results through a series of sensitivity and reverse direction analyses. The exposure and outcome datasets were substituted from the FinnGen and genome-wide association studies catalog databases. A meta-analysis on primary and validation analyses was performed to combine the estimates of MR study. Results: Based on the MR analysis results, eczema was associated with an increased risk of lung cancer (odds ratio [OR] = 1.0427, 95% confidence interval [CI] = 1.0082–1.0783, P = 0.0148) and brain cancer (OR = 1.0285, 95% CI = 1.0120–1.0452, P = 0.0007) and decreased risk of colorectal cancer (OR = 0.9324, 95% CI = 0.8774–0.9909, P = 0.0242) and malignant neoplasm of the kidney (OR = 0.9323, 95% CI = 0.8834–0.9839, P = 0.0108). The sensitivity analysis indicated that the results were stable and reliable, and the reverse MR analyses demonstrated no causation between the cancers of interest and eczema. Conclusions: Our results identified eczema as a genetic risk factor for lung and brain cancer and a protective factor for colorectal cancer and malignant neoplasm of the kidney. No connection was observed between eczema and other cancers. Further evidence from epidemiological and mechanistic studies is needed to elucidate these findings in detail.


  • Open Access

    N6‐methyladenosine‐mediated upregulation of LNCAROD confers radioresistance in esophageal squamous cell carcinoma through stabilizing PARP1

    by Xiaobo Shi, Xiaozhi Zhang, Xinran Huang, Ruijuan Zhang, Shupei Pan, Shan Huang, Yuchen Wang, Yue Ke, Wei Guo, Xiaoxiao Liu, et al.

    Background: Radiotherapy is a primary therapeutic modality for esophageal squamous cell carcinoma (ESCC), but its effectiveness is still restricted due to the resistance of cancer cells to radiation. Long non‐coding RNAs (lncRNAs) and N6‐methyladenosine (m6A) have been shown to play significant roles in tumour radioresistance. However, the precise manifestation and role of m6A‐modified lncRNAs in ESCC radioresistance remain unclear.Methods: Bioinformatics analysis was conducted to identify m6A‐modified lncRNAs implicated in the radioresistance of ESCC. A series of functional experiments were performed to investigate the function of LNCAROD in ESCC. Methylated RNA immunoprecipitation, chromatin isolation by RNA purification‐mass spectrometry, RNA immunoprecipitation, and co‐immunoprecipitation experiments were performed to explore the mechanism of m6A‐mediated upregulation of LNCAROD expression and the downstream mechanism enhancing the radioresistance of ESCC. The efficacy of LNCAROD in vivo was assessed using murine xenograft models.Results: Herein, we identified LNCAROD as a novel METTL3‐mediated lncRNA that enhanced radioresistance in ESCC cells and was post‐transcriptionally stabilised by YTHDC1. Moreover, we confirmed that LNCAROD prevented ubiquitin‐proteasome degradation of PARP1 protein by facilitating PARP1‐NPM1 interaction, thereby contributing to homologous recombination‐mediated DNA double‐strand breaks repair and enhancing the radiation resistance of ESCC cells. Silencing LNCAROD in a nude mouse model of ESCC in vivo resulted in slower tumour growth and increased radiosensitivity.Conclusion: Our findings enhance the understanding of m6A‐modified lncRNA‐driven machinery in ESCC radioresistance and underscore the significance of LNCAROD in this context, thereby contributing to the development of a potential therapeutic target for ESCC patients.


  • CD39 inhibitor (POM-1) enhances radiosensitivity of esophageal squamous cell carcinoma (ESCC) cells by promoting apoptosis through the Bax/Bcl-2/Caspase 9/Caspase 3 pathway

    by Yuchen Wang, Ruijuan Zhang, Xinran Huang, Xinyu He, Shangyi Geng, Shupei Pan, Wei Guo, Xiaoxiao Liu, Yongze Dang, Jingkun Qu, et al.


  • Open Access

    Causal associations between constipation and pan-cancer: a bidirectional Mendelian randomization study

    by Yongze Dang, Xinyu He, Xiaoxiao Liu, Yuchen Wang, Shangyi Geng, Yutong Cheng, Hongbing Ma, Xixi Zhao

    Objective: Observational studies have suggested a potential association between constipation and several cancers. However, the causal relationship between constipation and cancer remains unclear. The purpose of this study is to explore the potential causal relationship between constipation and pan-cancer using Mendelian Randomization (MR) methods.Methods: We performed a bidirectional MR analysis using publicly available summary data from Genome-Wide Association Studies (GWAS) statistics. The Inverse Variance Weighted (IVW) method was used as the main analysis method. We also used four MR methods: MR-Egger, Weighted Median, MR-PRESSO and MR.RAPS. Simultaneously, MR-Egger regression, Cochran’s Q test and MR-PRESSO Global test were used to estimate the pleiotropy and heterogeneity of SNPs. In addition, we performed “leave-one-out” analyses” to avoid bias caused by horizontal pleiotropy of individual SNPs.Results: MR analysis revealed a potential causal association between constipation and the risk of colorectal cancer (CRC) [IVW (OR= 1.0021 (1.0003, 1.0039), P= 0.0234)], lung cancer (LC) [IVW (OR=1.0955 (1.0134, 1.1843), P=0.0218)], Oral cavity and pharyngeal cancer (OPC) [IVW (OR=1.4068 (1.0070, 1.9652), P=0.0454)], and Pancreatic cancer (PC) [IVW (OR=1.5580 (1.0659, 2.2773), P=0.0221)]. In addition, we explored causal relationships between constipation and 12 other types of cancers, including gastric cancer, esophageal cancer, skin melanoma and so on. All five methods yielded no evidence of a causal association between constipation and the risk of these cancer types. In the reverse MR analysis, there was no evidence of a causal association between cancer and the risk of constipation for all five methods.Conclusion: Our bidirectional MR study suggests a potential relationship between constipation and an increased risk of CRC, LC OPC and PC. The underlying mechanisms behind these associations will need to be explored in future experimental studies.


  • Open Access

    Baicalein enhances immune response in TNBC by inhibiting leptin expression of adipocytes

    by Mengjie Liu, Chaofan Li, Jingkun Qu, Shiyu Sun, Zitong Zhao, Weiwei Wang, Wei Lv, Yu Zhang, Yifan Cai, Fang Zhao, et al.

    Triple‐negative breast cancer (TNBC) is a special pathological type of breast cancer (BC) with poor prognosis. Obesity is shown to be involved in TNBC tumor progression. The interaction between obesity and BC has generated great attention in recent years, however, the mechanism is still unclear. Here, we showed that leptin secreted by adipocytes upregulated PD‐L1 expression in TNBC through the p‐STAT3 signaling pathway and that baicalein inhibited PD‐L1 expression in tumor microenvironment by suppressing leptin transcription of adipocytes. Collectively, our findings suggest that leptin may be the key factor participating in obesity‐related tumor progression and that baicalein can break through the dilemma to boost the anti‐tumor immune response.


  • Open Access

    Prognostic Models Using Machine Learning Algorithms and Treatment Outcomes of Occult Breast Cancer Patients

    by Jingkun Qu, Chaofan Li, Mengjie Liu, Yusheng Wang, Zeyao Feng, Jia Li, Weiwei Wang, Fei Wu, Shuqun Zhang, Xixi Zhao

    Background: Occult breast cancer (OBC) is an uncommon malignant tumor and the prognosis and treatment of OBC remain controversial. Currently, there exists no accurate prognostic clinical model for OBC, and the treatment outcomes of chemotherapy and surgery in its different molecular subtypes are still unknown. Methods: The SEER database provided the data used for this study’s analysis (2010–2019). To identify the prognostic variables for patients with ODC, we conducted Cox regression analysis and constructed prognostic models using six machine learning algorithms to predict overall survival (OS) of OBC patients. A series of validation methods, including calibration curve and area under the curve (AUC value) of receiver operating characteristic curve (ROC) were employed to validate the accuracy and reliability of the logistic regression (LR) models. The effectiveness of clinical application of the predictive models was validated using decision curve analysis (DCA). We also investigated the role of chemotherapy and surgery in OBC patients with different molecular subtypes, with the help of K-M survival analysis as well as propensity score matching, and these results were further validated by subgroup Cox analysis. Results: The LR models performed best, with high precision and applicability, and they were proved to predict the OS of OBC patients in the most accurate manner (test set: 1-year AUC = 0.851, 3-year AUC = 0.790 and 5-year survival AUC = 0.824). Interestingly, we found that the N1 and N2 stage OBC patients had more favorable prognosis than N0 stage patients, but the N3 stage was similar to the N0 stage (OS: N0 vs. N1, HR = 0.6602, 95%CI 0.4568–0.9542, p < 0.05; N0 vs. N2, HR = 0.4716, 95%CI 0.2351–0.9464, p < 0.05; N0 vs. N3, HR = 0.96, 95%CI 0.6176–1.5844, p = 0.96). Patients aged >80 and distant metastases were also independent prognostic factors for OBC. In terms of treatment, our multivariate Cox regression analysis discovered that surgery and radiotherapy were both independent protective variables for OBC patients, but chemotherapy was not. We also found that chemotherapy significantly improved both OS and breast cancer-specific survival (BCSS) only in the HR−/HER2+ molecular subtype (OS: HR = 0.15, 95%CI 0.037–0.57, p < 0.01; BCSS: HR = 0.027, 95%CI 0.027–0.81, p < 0.05). However, surgery could help only the HR−/HER2+ and HR+/HER2− subtypes improve prognosis. Conclusions: We analyzed the clinical features and prognostic factors of OBC patients; meanwhile, machine learning prognostic models with high precision and applicability were constructed to predict their overall survival. The treatment results in different molecular subtypes suggested that primary surgery might improve the survival of HR+/HER2− and HR−/HER2+ subtypes, however, only the HR−/HER2+ subtype could benefit from chemotherapy. The necessity of surgery and chemotherapy needs to be carefully considered for OBC patients with other subtypes.


    • 1 January 2023
      • Vol. 13  (10) , 4508-+

    A novel web-based prognostic nomogram and the features influencing the curative effect of chemotherapy and radiotherapy for Paget's disease with invasive ductal carcinoma

    by Jingkun Qu, Chaofan Li, Mengjie Liu, Yusheng Wang, Shiyu Sun, Zeyao Feng, Fei Wu, Shuqun Zhang, Xixi Zhao

    Paget's disease (PD) of the breast is a rare underlying malignant tumor. Approximately 50% to 60% of patients with mammary PD are concurrently diagnosed with invasive ductal carcinoma (PD-IDC), a condition as-sociated with a worse prognosis than IDC without PD. Thus far, there has been a lack of an accurate and efficient prognostic model for PD-IDC, and the factors influencing the effectiveness of chemotherapy and radiotherapy for these patients remain unknown. In this study, we developed a web-based nomogram based on the data from the Surveillance Epidemiology and End Results (SEER) database. We subjected the model to a series of validation meth-ods, including area under the curve (AUC) values, receiver operating characteristic curve (ROC) analysis, calibration curves, and decision curve analysis (DCA). Our results demonstrated that our model exhibited high discrimination, accuracy, and clinical applicability in predicting the overall survival (OS) of patients with PD-IDC (testing set: three -and five-year AUCs, 0.831 and 0.841, respectively). To further validate our nomogram, we used external data from both our institution and sister hospitals (external data: three-and five-year AUCs, 0.892 and 0.914, respectively). Multivariable Cox regression analysis identified several independent unfavorable prognostic factors for the OS of patients with PD-IDC, including increasing age, high grade, widowed status, higher T stages, and the presence of bone metastases. Furthermore, propensity score matching (PSM)-adjusted analysis was conducted, revealing that chemotherapy did not significantly improve the survival of patients with PD-IDC across molecular subtypes, except for those in the grade III/IV group, where it improved both OS and breast cancer-specific survival (BCSS). Addition-ally, our findings indicated that only patients with PD-IDC with T4 and N3 stages benefited from radiotherapy, leading to improvements in both OS and BCSS. In conclusion, we have comprehensively analyzed the clinical characteristics and prognosis of patients with PD-IDC, culminating in the development of a user-friendly web-based nomogram for predicting their survival. Our predictive model is not only highly accurate but also offers simplicity, making it ac-cessible for healthcare providers and patients. Furthermore, our stratified analysis highlights that the pathological grade, rather than the molecular subtype, plays a pivotal role in determining the efficacy of chemotherapy in improv-ing the prognosis for patients with PD-IDC, while radiotherapy confers survival benefits to patients with PD-IDC in T4 and N3 stages.